Adamis Pharmaceuticals Corp
Company Snapshot: Adamis Pharmaceuticals Corp
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) is a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology and immunology. In its specialty pharmaceutical pipeline, ADMP is developing low cost therapeutic alternatives for the treatment of anaphylaxis, asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. Within the Company's biotechnology pipeline is a novel cell-based therapeutic cancer vaccine and three drug candidates for the treatment of prostate cancer.
- Jun 15 2017 Adamis Pharmaceuticals Receives FDA Approval for Its Epinephrine Pre-Filled Syringe
- Apr 26 2017 Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
- Apr 21 2017 Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
- Apr 20 2017 Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock